ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

VRPX Virpax Pharmaceuticals Inc

0,7551
-0,0449 (-5,61%)
18 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Virpax Pharmaceuticals Inc VRPX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,0449 -5,61% 0,7551 01:58:54
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,81 0,77 0,8199 0,781 0,80
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
17.5.202422:05EDGAR2Form 8-K - Current report
16.5.202422:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
15.5.202414:00BWVirpax Announces Pricing of $2.25 Million Public Offering
15.5.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
13.5.202423:30EDGAR2Form S-1/A - General form for registration of securities..
13.5.202422:20EDGAR2Form 8-K - Current report
13.5.202422:10BWVirpax Pharmaceuticals Reports 2024 First Quarter Results..
13.5.202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30.4.202413:30BWVirpax Announces Results of Maximum Tolerated Dose Study for..
26.3.202412:30BWVirpax Pharmaceuticals Reports 2023 Year-End Results
27.2.202413:31BWVirpax Pharmaceuticals Announces Reverse Stock Split to..
27.2.202413:30BWVirpax Pharmaceuticals Announces Proposed Settlement of..
07.2.202413:30BWVirpax Pharmaceuticals Announces Preliminary Results of..
31.1.202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31.1.202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.12.202313:30EDGAR2Form 8-K - Current report
29.12.202313:30BWVirpax Pharmaceuticals Announces Results of Special..
13.12.202314:30EDGAR2Form 8-K - Current report
07.12.202315:08EDGAR2Form DEF 14A - Other definitive proxy statements
07.12.202314:58EDGAR2Form 8-K - Current report
07.12.202314:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21.11.202322:57EDGAR2Form PRE 14A - Other preliminary proxy statements
17.11.202313:30EDGAR2Form 8-K - Current report
17.11.202313:15EDGAR2Form 8-K - Current report
17.11.202313:10BWVirpax Pharmaceuticals Announces Notification from Nasdaq..
17.11.202313:00BW Virpax Pharmaceuticals Announces Leadership Transition
16.11.202322:51EDGAR2Form 8-K - Current report
15.11.202322:15BWVirpax Pharmaceuticals Reports 2023 Third Quarter Results..
15.11.202321:03EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
31.10.202313:58BWVirpax Pharmaceuticals Announces that Envelta™ Remains on..
12.10.202314:02BWVirpax Pharmaceuticals Announces Extension of CRADA with the..
11.10.202322:10EDGAR2Form 8-K - Current report
03.10.202315:51EDGAR2Form 3 - Initial statement of beneficial ownership of..
02.10.202314:58BWGerald W. Bruce Appointed President and CEO of Novvae™..
27.9.202314:58BWVirpax Pharmaceuticals Announces Results of Probudur™ Dose..
26.9.202314:58BWVirpax Pharmaceuticals to Present at the LD Micro Main Event..
21.9.202319:35BWAltasciences von Virpax ausgewählt, um die Entwicklung eines..
21.9.202319:18BWAltasciences choisi par Virpax pour soutenir le..
21.9.202316:00BWAltasciences Chosen by Virpax to Support the Development of..
18.9.202313:58BWVirpax Pharmaceuticals Announces the Formation of Novvae™..
05.9.202315:28EDGAR2Form 8-K - Current report
05.9.202315:00BWVirpax Pharmaceuticals Updates on Litigation
28.8.202314:58BWVirpax® Pharmaceuticals to Present at H.C. Wainwright 25th..
16.8.202323:00EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht